InsiderSource
PHAT

Phathom Pharmaceuticals, Inc.

SEC CIK 1783183
$10.71 −13.7% · 90 days
90-day buys
$0
0 open-market
90-day sells
$0
0 open-market
Net insider flow
+$0
Net buying
Filings shown
82
Most recent
Advertisement

At a glance

Insiders at PHAT have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.

Largest recent trade: Takeda Pharmaceutical Co Ltd sold $30M of PHAT, trimming their stake 50%.

Most active filer: Takeda Pharmaceutical Co Ltd, with 40 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for PHAT, newest first
View on SEC EDGAR ↗
PHAT
Phathom Pharmaceuticals, Inc.
Buy Topper James N · Director · Open-market purchase · filed May 23, 2025 ΔOwn +6.8%

Topper James N, PHAT's Director, spent $14.6K of their own money on 3,780 shares at $4, growing their stake 7%.

+$14.6K
3,780 sh @ $4
Advertisement
PHAT
Phathom Pharmaceuticals, Inc.
Buy Topper James N · Director · Open-market purchase · filed May 15, 2025 ΔOwn +13%

Topper James N, PHAT's Director, spent $20.9K of their own money on 6,300 shares at $3, growing their stake 13%.

+$20.9K
6,300 sh @ $3
PHAT
Phathom Pharmaceuticals, Inc.
Buy Topper James N · Director · Open-market purchase · filed May 15, 2025 ΔOwn +2.3%

Topper James N, PHAT's Director, spent $3.5K of their own money on 1,120 shares at $3, growing their stake 2%.

+$3.5K
1,120 sh @ $3
PHAT
Phathom Pharmaceuticals, Inc.
Buy Topper James N · Director · Open-market purchase · filed May 13, 2025 ΔOwn +35%

Topper James N, PHAT's Director, spent $38.3K of their own money on 12,601 shares at $3, growing their stake 35%.

+$38.3K
12,601 sh @ $3
PHAT
Phathom Pharmaceuticals, Inc.
Buy Topper James N · Director · Open-market purchase · filed May 13, 2025 ΔOwn NEW

Topper James N, PHAT's Director, spent $106.6K of their own money on 33,376 shares at $3, opening a brand-new position.

+$106.6K
33,376 sh @ $3
PHAT
Phathom Pharmaceuticals, Inc.
Buy Topper James N · Director · Open-market purchase · filed May 13, 2025 ΔOwn +6.7%

Topper James N, PHAT's Director, spent $8.1K of their own money on 2,226 shares at $4, growing their stake 7%.

+$8.1K
2,226 sh @ $4
PHAT
Phathom Pharmaceuticals, Inc.
Buy KARBE FRANK · Director · Open-market purchase · filed Dec 16, 2024 ΔOwn +28%

Karbe Frank, PHAT's Director, spent $99.1K of their own money on 12,500 shares at $8, growing their stake 28%.

+$99.1K
12,500 sh @ $8
Advertisement

About PHAT insider activity

This page tracks every recent Form 4 filed for Phathom Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is PHAT insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Phathom Pharmaceuticals, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.